New insider activity at Apellis Pharmaceuticals ( (APLS) ) has taken place on January 21, 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Apellis Pharmaceuticals has seen a wave of insider selling across its top leadership team, with multiple executives cashing out portions of their holdings. CSO Pascal Deschatelets sold 909 shares for $17,989, while CFO Timothy Eugene Sullivan disposed of 2,892 shares worth $57,232. GC David O. Watson offloaded 2,475 shares for $48,980, and CEO Cedric Francois led the group in volume with the sale of 8,182 shares totaling $161,921. VP and Chief Accounting Officer James George Chopas sold 726 shares for $14,367, and CTO Nur Nicholson sold 2,203 shares for $43,597. Chief Business & Strategy Officer Mark Jeffrey DeLong parted with 1,334 shares for $26,399, and CMO Caroline Baumal sold 1,882 shares for $37,244. Together, these transactions highlight significant coordinated selling activity by Apellis’s senior executives across the organization.
Recent Updates on APLS stock
Over the last 24 hours, Apellis Pharmaceuticals’ shares have dropped sharply, trading down about 17% to the low-$20s following its Q4 / FY25 preliminary update around the JPMorgan healthcare conference, which triggered a flurry of analyst revisions. BofA upgraded the stock while keeping its target level unchanged, arguing that the current valuation underestimates the commercial potential of Empaveli in new rare kidney disease indications and highlighting stronger-than-expected launch metrics, including rapid uptake among the U.S. patient population. Separately, BofA had earlier nudged its target higher after the same Q4 pre-announcement, reflecting a somewhat improved view of the company’s near-term fundamentals. In contrast, Wells Fargo cut its target because Empaveli’s C3G/IC-MPGN ramp is coming in slower than previously modeled, leading the firm to materially reduce its 2026–2030 revenue forecasts, though it left Syfovre expectations largely intact as that product’s pre-filled syringe launch is seen as a “show-me” event. Cantor Fitzgerald also trimmed its target following the Q4 pre-announcement: while it views the C3G launch as progressing well, it cited Apellis’ decision not to provide formal guidance as a key factor weighing on sentiment and contributing to the stock’s decline despite otherwise constructive product trends.
Spark’s Take on APLS Stock
According to Spark, TipRanks’ AI Analyst, APLS is a Neutral.
The overall stock score reflects a mixed outlook for Apellis Pharmaceuticals. Financial performance shows improvement, particularly in cash flow, but revenue growth and profitability remain volatile. Technical analysis indicates mixed momentum with potential overbought conditions. The high P/E ratio suggests overvaluation, adding risk if earnings do not meet expectations. The earnings call provided positive guidance, but challenges remain in revenue growth and patient access.
To see Spark’s full report on APLS stock, click here.
More about Apellis Pharmaceuticals
YTD Price Performance: -18.51%
Average Trading Volume: 2,788,029
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.52B